Lynk Pharmaceuticals has dosed the first patient in a Phase II clinical trial of LNK01004 ointment for vitiligo. The tr...
MEDIPOST has treated the first U.S. participant in its Phase III clinical trial evaluating an investigational mesenchyma...
Delonix Bioworks has dosed the first participant in its Phase 1 clinical trial of DX-104, a next-generation Group B meni...
Cell Therapies is pleased to support the launch of the CARTiEr E312 Phase I/Ib clinical trial in Australia, evaluating A...
West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, has anno...
FibroBiologics has completed manufacturing of the third batch of CYWC628 drug product for its ongoing Phase 1/2 clinical...
Insilico Medicine has initiated a Phase III clinical trial of rentosertib, its AI-discovered oral small-molecule TNIK in...
Brii Biosciences has reported topline end-of-treatment data from its ongoing Phase 2b ENRICH and ENHANCE studies evaluat...
Ascletis Pharma has submitted two Investigational New Drug applications to the U.S. FDA for obesity treatment candidates...
Viking Therapeutics has initiated a Phase 1 clinical study of VK3019, an investigational dual amylin and calcitonin rece...
NeuroSense Therapeutics has reported positive biomarker findings from its Phase 2 RoAD proof-of-concept study of PrimeC ...
Innovative Molecules has dosed the first patient in its Phase 2a clinical trial evaluating adibelivir for recurrent geni...
Cryoport’s IntegriCell cryopreservation services have been selected by Verismo Therapeutics to support the company...
Servier has enrolled the first U.S. patient in a Phase Ib/II first-in-human clinical study evaluating an investigational...
Ollin Biosciences has completed an oversubscribed US$330 million Series B financing to advance global Phase III developm...
Innovent Biologics has dosed the first patient in the Chinese pivotal Phase III TriadicMM-1 trial of IBI3003 for relapse...
CeleCor Therapeutics has completed submission of its New Drug Application to the U.S. FDA for zalunfiban, its investigat...
Phanes Therapeutics has completed enrolment in its Phase II study of spevatamig in combination with standard-of-care che...
The search for safer and more effective pain therapies remains one of medicine's most pressing challenges. Despite advan...
Cancer immunotherapy is entering a new phase—one that extends beyond targeting individual tumour cells and towards...
As biotechnology enters an increasingly data-driven era, organisations are rethinking how discovery, clinical developmen...
Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, today announced ...
Insilico Medicine has completed first-in-human dosing in the Phase I clinical study of ISM8969, an AI-driven small-molec...
The Tang Prize Foundation has awarded the 2026 Tang Prize in Biopharmaceutical Science to three pioneers of cellular imm...
Niowave and Ratio Therapeutics have signed a supply agreement for Actinium-225, strengthening Ratio’s access to a ...
